Press release
Malignant Pleural Mesothelioma Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight | MolMed, PharmaMar, Ys Therapeutics, Merck Sharp & Dohme C
Malignant Pleural Mesothelioma Clinical Trials
"Malignant Pleural Mesothelioma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Malignant Pleural Mesothelioma Therapeutics Market.
The Malignant Pleural Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The Malignant Pleural Mesothelioma pipeline report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Malignant Pleural Mesothelioma Overview:
Malignant pleural mesothelioma (MPM) is an aggressive cancer that affects the pleural surface. It is commonly linked to previous asbestos exposure, with a latency period of about 40 years between exposure to the fibers and the onset of the disease. The global incidence of MPM has been steadily increasing over the past decade and is expected to reach its peak around 2020. The prognosis for MPM is poor, with median survival ranging from 8 to 14 months after diagnosis. Women tend to have a more favorable prognosis than men, but because the disease is primarily occupational, it is more common in men, with a male-to-female ratio of 4:1. There are four main histological subtypes of MPM: epithelioid, sarcomatoid, biphasic (mixed), and desmoplastic. Most cases of MPM are attributed to asbestos exposure, which often occurred more than 40 years ago. Other causes include erionite (a mineral found in Turkey), chest wall radiation, and simian virus.
Download malignant pleural mesothelioma pipeline insights report @ https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Malignant Pleural Mesothelioma Pipeline Report
• DelveInsight's Malignant Pleural Mesothelioma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Malignant Pleural Mesothelioma treatment.
• In February 2025, Ferring Ventures Limited announced results of a Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma
• In January 2025, Nurix Therapeutics, Inc. announced results of a Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
• In January 2025, Context Therapeutics Inc announced results of Phase 1 Study of CT-95 in Advanced Cancers Associated with Mesothelin Expressionz
• In January 2025, ETOP IBCSG Partners Foundation announced results of a Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
• In September 2024, The FDA has approved Merck's KEYTRUDA® (pembrolizumab) in combination with pemetrexed and platinum chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
• Key Malignant Pleural Mesothelioma companies such as MolMed, PharmaMar, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Novartis, Bristol-Myers Squibb, Novartis, TCR2 Therapeutics, Novotech (Australia) Pty Limited, AstraZeneca, Hoffmann-La Roche, Polaris Pharmaceuticals, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others are evaluating new drugs for Malignant Pleural Mesothelioma to improve the treatment landscape.
• Promising Malignant Pleural Mesothelioma pipeline therapies in various stages of development include Semaglutide, ACP 01, Revacept, and others.
Malignant Pleural Mesothelioma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Malignant Pleural Mesothelioma Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Malignant Pleural Mesothelioma market.
Request for a detailed informative report on malignant plural mesothelioma pipeline insights @ https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Malignant Pleural Mesothelioma Emerging Drugs
• NGR-TNF: MolMed
• Pembrolizumab : Merck & Co
• Pegargiminase: Polaris Pharmaceuticals
• Lurbinectedin: PharmaMar
• YS110: Ys Therapeutics
Malignant Pleural Mesothelioma Companies
Over 20 major companies are working on developing therapies for Malignant Pleural Mesothelioma. Among them, MolMed has drug candidates for the condition in the most advanced stage, specifically Phase III.
DelveInsight's report covers around 22+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Malignant Pleural Mesothelioma Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Download Sample Pages to Get an in-depth Assessment of the Emerging Malignant Pleural Mesothelioma Therapies and Key Companies: Malignant Pleural Mesothelioma Clinical Trials and advancements @ https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment
• Malignant Pleural Mesothelioma Assessment by Product Type
• Malignant Pleural Mesothelioma By Stage
• Malignant Pleural Mesothelioma Assessment by Route of Administration
• Malignant Pleural Mesothelioma Assessment by Molecule Type
Download Malignant Pleural Mesothelioma Sample report to know in detail about the Malignant Pleural Mesothelioma treatment market @ Malignant Pleural Mesothelioma Therapeutic Assessment - https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Report Introduction
2. Executive Summary
3. Malignant Pleural Mesothelioma Current Treatment Patterns
4. Malignant Pleural Mesothelioma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Malignant Pleural Mesothelioma Late-Stage Products (Phase-III)
7. Malignant Pleural Mesothelioma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Malignant Pleural Mesothelioma Discontinued Products
13. Malignant Pleural Mesothelioma Product Profiles
14. Malignant Pleural Mesothelioma Key Companies
15. Malignant Pleural Mesothelioma Key Products
16. Dormant and Discontinued Products
17. Malignant Pleural Mesothelioma Unmet Needs
18. Malignant Pleural Mesothelioma Future Perspectives
19. Malignant Pleural Mesothelioma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Malignant Pleural Mesothelioma Pipeline Reports Offerings: @https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Malignant Pleural Mesothelioma Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight | MolMed, PharmaMar, Ys Therapeutics, Merck Sharp & Dohme C here
News-ID: 4125010 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Malignant
Malignant Mesothelioma Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Malignant Mesothelioma Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections-Pipeline Review, H2 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape.
Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.
Report Highlights
Publisher's Pharmaceutical…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result,…
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview
4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. Global Malignant Melanoma Drug Market Future Prospects
6. Global Malignant Melanoma Clinical Pipeline By…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
